What it is
Neuroxelin is a proprietary or undefined blend name used for a neuroprotective-style stack. No fixed ingredient list or source-backed human protocol is established.
Evidence boundary
No validated human protocol is available.
Preparation and measurement
Reconstitution: 48 mg vial + 3 mL BAC = 16 mg/mL.
Concentration matches.
Reference schedule
| Phase | Dose | Draw / measure | Frequency | Weekly total |
|---|---|---|---|---|
| Weeks 1–4 | 500 mcg (0.5 mg) | 3 units (0.03 mL) | 1x/day | 3.5 mg/week |
| Weeks 5–8 | 750 mcg (0.75 mg) | 4.7 units (0.047 mL) | 1x/day | 5.25 mg/week |
Weeks 1–4
- Dose
- 500 mcg (0.5 mg)
- Draw / measure
- 3 units (0.03 mL)
- Frequency
- 1x/day
- Weekly total
- 3.5 mg/week
Weeks 5–8
- Dose
- 750 mcg (0.75 mg)
- Draw / measure
- 4.7 units (0.047 mL)
- Frequency
- 1x/day
- Weekly total
- 5.25 mg/week
Weekly totals apply only during the active phase.
Titration rules
-
Use 500 mcg daily for weeks 1–4. The source schedule increases to 750 mcg daily for weeks 5–8 only after the full first phase.
-
Do not extrapolate the schedule to a differently formulated product.
-
Use a syringe with half-unit markings because both draws are below 5 U.
-
Whether the ingredient list is actually known
-
Whether the use case is being confused with related neuropeptides
-
Headache, dizziness, sleep changes, mood changes, and injection-site reactions if anyone is comparing notes
Practical rules
- Treat this as an undefined blend name, not a standard protocol.
- Do not use related-peptide studies as proof that the blend works.
- Keep the interpretation clearly separate from source-backed single compounds.